首页>
外文期刊>Prescrire international
>Icosapent ethyl (vazkepa°) in cardiovascular prevention Uncertain reduction in cardiovascular mortality, and established, unjustified harms
【24h】
Icosapent ethyl (vazkepa°) in cardiovascular prevention Uncertain reduction in cardiovascular mortality, and established, unjustified harms
展开▼
机译：Icosapent ethyl (vazkepa°) in cardiovascular prevention Uncertain reduction in cardiovascular mortality, and established, unjustified harms
In a large double-blind randomised trial versus liquid paraffin in over 8000 statin-treated patients with l1ypertrjglycerjc|aemja anc| cardiovascular risk factors, icosapent ethyl (which releases an omega-3 fatty acid in the gastrointestinal tract) appeared to slightly reduce cardiovascular mortality, without reducing all-cause mortality. But these results are weakened by the fact that the choice of liquid paraffin as the comparator could have favoured icosapent ethyl, and no detailed results are available on patients at particularly high risk due to prior cardiovascular events. In primary cardiovascular prevention, icosapent ethyl did not appear to improve clinical outcomes. Its adverse effects include cardiac arrhythmias (atrial fibrillation and atrial flutter) and potentially serious bleeding. In practice, it is best to avoid these risks in light of icosapent ethyl's uncompelling evaluation, just as it is better to avoid taking omega-3 supplements, and to adopt a Mediterranean-type diet instead.
展开▼
